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Abstract
High cell-surface GnRH receptor (GnRH-R) levels have been shown to have a major influence on the extent of GnRH agonist-
mediated tumor growth inhibition. The ability of the GnRH agonist leuprorelin acetate (LA) to induce a post-transcriptional
upregulation of GnRH-R at the plasma membrane of androgen-sensitive (LNCaP) and -insensitive (PC-3) prostate cancer
(PCa) cells has been previously demonstrated by Western blotting. Here we performed single molecule force spectroscopy
by using Atomic Force Microscopy (AFM), which has proven to be a powerful tool allowing for investigation of living cell
surface biological features, such as the so far unclear GnRH agonist/receptor interaction. Thus, in the hormone-insensitive
PC-3 cells, we characterized the strength of the LA-receptor binding, and the amount and distribution of the functional
receptor molecules on the cell surface. The effect of a long and continuous treatment (up to 30 days) with the agonist
(10211 and 1026 M) on the same parameters was also investigated. A GnRH-R increase was observed, reaching the
maximum (,80%) after 30 days of treatment with the highest dose of LA (1026 M). The analogue-induced increase in GnRH-
R was also demonstrated by Western blotting. In addition, two different receptor bound strengths were detected by AFM,
which suggests the existence of two GnRH-R classes. A homogeneous distribution of the unbinding events has been found
on untreated and treated PC-3 cell surfaces. The persistence of high receptor levels at the membrane of these living cells
may warrant the maintenance of the response to LA also in androgen-unresponsive PCa. Moreover, the determination of
ligand/receptor bond strength could shed light on the poorly understood event of LA/GnRH-R interaction and/or address
structural/chemical agonist optimizations.
Citation: Lama G, Papi M, Angelucci C, Maulucci G, Sica G, et al. (2013) Leuprorelin Acetate Long-Lasting Effects on GnRH Receptors of Prostate Cancer Cells: An
Atomic Force Microscopy Study of Agonist/Receptor Interaction. PLoS ONE 8(1): e52530. doi:10.1371/journal.pone.0052530
Editor: Antimo Migliaccio, II Universita` di Napoli, Italy
Received December 29, 2011; Accepted November 19, 2012; Published January 9, 2013
Copyright:  2013 Lama et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Takeda Italia Farmaceutici SpA partially supported this work. The funders had no role in study design, data collection and analysis, decision to publish,
or preparation of the manuscript. No additional external funding was received for this study.
Competing Interests: In 2010, Takeda Italia Farmaceutici SpA gave the authors a voluntary donation to support the scientific research of their Institute, not
specifically related to this work. The authors indicated the name of the company in fairness. This does not alter the authors’ adherence to all the PLOS ONE
policies on sharing data and materials. The authors have declared that no competing interests exist.
* E-mail: gigliola@rm.unicatt.it
. These authors contributed equally to this work.
Introduction
The gonadotropin-releasing hormone (GnRH), a decapeptide
secreted in a pulsatile fashion by hypothalamic neurons, controls
gonadotropin synthesis and release by activating receptors (type I
GnRH-R) expressed on anterior pituitary cells. The down-
regulation and desensitization of these hypophyseal receptors by
continuous administration of GnRH agonistic analogues represent
the rationale for the clinical use of these hormones in the therapy
of endocrine-related cancers since it leads to gonadal steroid
suppression [1–3]. The finding of GnRH/GnRH-R expression in
these tumors, as well as in nonmalignant tissues [4–7], disclosed
the possibility for cells of extrapituitary tissues to be directly
affected by GnRH analogues. Different studies demonstrated the
inhibitory effect of GnRH agonists on the growth of various
neoplasms including prostate cancer (PCa) cells [6,8–14]. Never-
theless, some authors reported that GnRH agonists are ineffective
when used alone while counteract or even suppress hormone- or
growth factor-stimulated cell proliferation [15–19]. In addition,
they demonstrated that these compounds are able to modulate
PSA expression as well as the expression of several genes/proteins
regulating growth and differentiation, apoptosis or cell/cell
adhesion [20–23]. More recently, the effects of the GnRH
agonistic analogue leuprorelin acetate (LA) on the expression of
GnRH-R were investigated by Western blotting in two human
PCa cell lines: the androgen-sensitive, well-differentiated and low
invasive LNCaP cells and the androgen-insensitive, poorly
differentiated and highly invasive PC-3 cells [24]. In these two
models, the analogue at both low and high concentrations is
effective in inducing a post-transcriptional enhancement of the
receptor expression at the plasma membrane level, after 4, 6 and
12 days of a continuous treatment.
The increase in receptor availability at the cell surface could be
a relevant therapeutic issue since it may warrant the maintenance
of the response to the agonist therapy [25]. Moreover, it may allow
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for the development of new therapeutic strategies, which is
particularly important for those tumors that either fail to respond
or develop resistance to endocrine therapy. In fact, even if it is
sorely difficult to predict the PCa cell behaviour in vivo, it is
presumable that, even in hormone-unresponsive PCa, the agonist
administration may provide a beneficial outcome also due to the
direct effect.
In the present paper, we performed single molecule force
spectroscopy by means of Atomic Force Microscopy (AFM) with
the aim of characterizing the strength of the LA-receptor binding,
and the amount and distribution of the functional receptor
molecules at the androgen-unresponsive PC-3 cell surface. We also
demonstrated the effect of a long and continuous treatment with
the agonist on the same parameters. AFM indeed allows for the
detection of dynamic changes in the mechanical properties of
living cell surface [26,27], as well as measurements in air or fluid of
unstained and uncoated biological samples in controlled environ-
ments and in a nanoscale resolution [28–31], without the
requirement of any special treatment that can result in cell
destruction or alteration. Moreover, single molecule force spec-
troscopy offers a unique opportunity to detect molecular
recognition between individual ligands and receptors. Since the
persistence of high receptor levels at the plasma membrane after a
relatively long and continuous treatment with GnRH agonist may
improve the efficacy of LA in androgen-unresponsive PCa, we
investigated the effect of the agonist at low and high concentra-
tions in PC-3 cells for up to 30 days. Intriguing information on so
far unclear GnRH agonist-receptor interaction may derive from
the study of the strength to which such binding occurs and address
structural/chemical optimizations of the analogue.
Materials and Methods
Cell lines and culture conditions
The human hormone-insensitive PC-3 cells [32] were kindly
donated by Prof F. Labrie (Laval University, Quebec, Canada).
Cells were routinely cultured on 25-cm2 cell culture flasks in
Dulbecco’s modified Eagle’s medium (DMEM, Euroclone S.p.A.,
Milan, Italy), supplemented with 5% foetal bovine serum (FBS,
Euroclone), antibiotics (100 IU/ml penicillin, 100 mg/ml strepto-
mycin, Euroclone), 10 mM Hepes buffer solution (Euroclone),
1 mM sodium piruvate (Euroclone) and 2 mM L-glutamine
(Euroclone).
The human embryonic kidney cells (HEK293) not expressing
any endogenous GnRH-R were kindly provided by Prof R. P.
Millar (Medical Research Council Human Reproductive Sciences
Unit, The Queen’s Medical Research Institute, Edinburgh, UK),
who obtained them from American Type Tissue Culture
Collection. HEK293 cells stably transfected with GnRH-R
(HEK293[SCL60]) were a gift from Prof. R. P. Millar and were
generated in his laboratory [33]. HEK293 and HEK293[SCL60]
cells were used as negative and positive control for GnRH-R
expression, respectively. Cells were cultured in DMEM, supple-
mented with 10% FBS, antibiotics (100 IU/ml penicillin, 100 mg/
ml streptomycin), 10 mM Hepes buffer solution, 1 mM sodium
piruvate and 4 mM L-glutamine.
All the cell lines were incubated in a humidified atmosphere of
5% CO2-95% air at 37uC.
Cell treatments
The cells were seeded at a density of 25,000 cells/ml of standard
culture medium in 40-mm TPP dishes (Techno Plastic Products
AG, Trasadingen, Switzerland). Once they adhered to the culture
plates (after 24 h), the medium was renewed with DMEM
supplemented with 5% charcoal-treated FBS (CH-FBS) and
1026 M or 10211 M LA (kindly donated by Takeda Pharmaceu-
tical Company Limited, Osaka, Japan).
The medium was changed every 48 h, while LA was added
daily to the cultures. PC-3 cells were exposed to the analogue for 6,
12, 18, 24 and 30 days.
Every six days, cells were trypsinized, seeded (25,000 cells/ml)
into the 40-mm TPP dishes and, once they adhered to the culture
plates, treated as described above for a further 6-day period. At the
end of each treatment period, the cells were analyzed by AFM. In
all the experiments, control cultures were run in parallel.
Atomic Force Microscopy (AFM)
All the measurements were performed by using an atomic force
microscope Nanowizard II (JPK Instruments, Berlin, Germany)
combined with an optical microscope Axio Observe (Zeiss,
Oberkochen, Germany). All the acquisitions were fulfilled in a
PBS solution (pH = 7.4), under a controlled temperature of 37uC.
AFM Probe Preparation
In order to investigate specific interactions between LA and
GnRH-R on the surface of PC-3 cells, the analogue molecules
were immobilized onto AFM tips. Rectangular soft silicon nitride
microcantilevers with ultrasharp conical tips with a radius of
,10 nm coated on both sides with gold (CSC16, MicroMash, San
Jose, CA) and calibrated as reported by Papi et al. [34] were used.
Prior to immobilization, microcantilevers were washed in
chloroform to remove oils and gross contaminants and then
exposed for 20 min to a UV-ozone cleaner in order to remove
organic and other oxidizable surface contaminants.
The analogue molecule immobilization procedure, a frequently
used method for tip functionalization with a ligand molecule [35],
is based on the use of an 8 nm long flexible cross-linker (pyridyl
dithio-Polyethyleneglycol-succinimidylpropionate, PDP-PEG-
NHS, Polypure). The clean cantilever was immediately immersed
in a PDP-PEG-NHS/chloroform solution for 3 h (linker concen-
tration: 2 mg/ml) and then, after two rinsing steps in chloroform
and one in PBS, treated with a drop of LA solution (2 mg/ml)
overnight.
After functionalization, cantilevers were thoroughly washed
three times in buffer solution and then stored at 4uC under sterile
conditions for further use in the experiments. Storage time was
always ,1 week. Any significant change in the LA/GnRH-R
interaction was observed during this period. Prior to being used,
the spring constant of each cantilever was calibrated by using the
thermal method [36].
Atomic Force Spectroscopy
To explore single molecular interactions, the dissociation
process of a tip-bound ligand from a cell surface-bound receptor
was studied by applying a pulling force to the ligand-receptor
complex until the binding between ligand and receptor broke.
Interaction forces of tip-bound ligands and surface immobilized
receptors were measured in force-distance cycles. At a fixed
position, the tip was approached to the cell surface and then
withdrawn after a determined time interval (0.5 s) while the
bending of the cantilever was observed. During this cycle, the
bending of the cantilever, which is proportional to the force, was
continuously measured and plotted versus tip-surface separation
(i.e. distance). Two representative force-distance curves are
reported in Fig. 1, when ligand/receptor interactions are not
detected (black square) and when a ligand/receptor interaction is
detected (red circles). At the beginning of the tip-surface approach,
the cantilever deflection remains zero. Upon tip-surface contact,
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the cantilever bends upwards, consistent with a repulsive force that
increases with the indentation. Subsequent tip-surface retraction
(Fig. 1) first leads to relaxation of the cantilever bending until the
repulsive force drops to zero. Upon further retraction, if the
interaction between the ligand and the receptor occurs, the
cantilever progressively bends downwards, reflecting an attractive
force that rises with increasing tip-surface separation (Fig. 1, red
circles). In every single experiment, for each time point, ,1000
force-distances curves were performed.
Western blot analysis
Plasma membrane-enriched fractions were prepared from 6-day
cultured PC-3, HEK293 and HEK293[SCL60] cells, according to
the protocol reported by Limonta et al. [37]. The same procedure
was used on PC-3 cells untreated or treated with LA (1026 M or
10211 M) for 6, 12, 18, 24 and 30 days. Samples were
homogenized in 10 mM Tris-HCl (pH 7.6) buffer containing
1 mM dithiothreitol on ice. The homogenates were centrifuged
two times for 10 min each at 800 g to remove cellular debris and
the resulting supernatants were centrifuged at 18,000 g to pellet
down the membrane fractions. The pellets were solubilized in
RIPA buffer [50 mM Tris-HCl (pH 7.7), 150 mM NaCl, 0.8%
Triton X-100, 0.8% sodium deoxycholate, 0.08% SDS, 10 mM
EDTA, 100 mM Na3VO4, 50 mM NaF, 0.3 mM PMSF, and
5 mM iodoacetic acid]. Protein samples (100 mg/lane) were
electrophoresed on a 10% polyacrylamide gel under reducing
conditions. Proteins were then electroblotted onto a polyvinylidene
difluoride membrane (Immobilon P, Millipore, Bedford, MA,
USA) which was probed (overnight, 4uC) with the mouse
monoclonal anti-GnRH-R antibody (Lab Vision Corporation,
Fremont, CA, USA) (1:100) in TBS containing 0.02% Tween 20
(TBS-T) and 5% nonfat dried milk (blocking buffer). The blot was
then overlaid with the HRP-labeled secondary antibody (Vector,
Burlingame, CA, USA; 1:5,000) for 40 min in blocking buffer at
room temperature. The protein bands were detected using an
enhanced chemiluminescence system (ECL, Amersham, Buck-
inghamshire, UK) and visualised on Hyperfilm ECL (Amersham).
Membranes were reprobed with an anti b-actin mAb (Sigma-
Aldrich, St. Louis, MO, USA; 1:10,000) as an internal control for
protein loading. The signals were quantitated by densitometry
(Chemi Doc Documentation System/Quantity One quantitation
software, Bio-Rad Laboratories, Hercules, CA, USA). Densito-
metric units of the protein of interest were then corrected for the
densitometric units of b-actin. The specific protein/b-actin ratio
from each treated sample was divided by the value obtained under
control conditions to obtain the fold change in GnRH-R level.
Statistical analysis
Data were analyzed by one-way ANOVA followed by Tukey’s
multiple comparison test. A value of p,0.05 was considered
statistically significant.
Results
GnRH-R quantification and binding strength in untreated
PC-3 cells
In Fig. 2A a representative distribution of unbinding events
(,1000 force-distance cycles at a rate of 2 mm/s) obtained on
untreated PC-3 cells after 6 days is shown. The bimodal
distribution is characterized by the presence of two, well evident
peaks, each recovered by a Gaussian fit. The first peak (purple line)
was detected at a lower force (f,37 pN) while the second one
(green line) at a higher force (f,65 pN). The presence of these two
peaks suggests the existence of two distinct interactions. From the
bimodal distribution, an overall unbinding probability (i.e. the
probability to record an unbinding event from a single force-
distance curve) of about 13% was obtained (Fig. 2A, blue line).
The bimodal distribution together with the unbinding probability
did not change for up to 30 days (data not shown).
To evaluate the amount of possible non-specific unbinding
events occurring due to the specific tip functionalization procedure
and the sensitivity of our approach, we performed the same force
spectroscopy experiments on HEK293 and HEK293[SCL60] cells.
As expected, in wild type HEK293 cells very few tip/sample
interactions were found (,3%). On the contrary, in the GnRH-R-
expressing HEK293[SCL60] cells several tip/sample interactions
were detected (,59%). Interestingly, in these cells the bimodal
distribution of unbinding forces was not evident since the
unbinding events at higher forces (,65 pN) are clearly less
probable compared to the more frequent unbinding events at
lower forces of ,37 pN (Fig. 2C).
GnRH-R quantification and binding strength in treated
PC-3 cells
An increase in the agonist/GnRH-R unbinding events was
observed in PC-3 cells during 30 days of exposure to LA (1026 M
or 10211 M) (Fig. 3A). The enhancement was detectable at all the
time intervals considered (from the 6th to the 30th day; p,0.001)
and it reached the maximum value of ,80% compared to control
after 30 days of treatment with the highest dose of the analogue. A
statistically significant difference was always found in the effect
triggered by the two drug concentrations, with the highest dose
being more effective in promoting the increase.
The same bimodal distribution (with one pick at f,37 pN and
another at f,65 pN) detected in untreated PC-3 cells was
observed in LA-treated cells over time (from the 6th to the 30th
day), regardless the treatment administered to the cells. In Fig. 2B,
a representative distribution of the unbinding events obtained at a
rate of 2 mm/s in PC-3 cells treated for 30 days with 1026 M LA is
illustrated. The blue curve shows the bimodal distribution of the
Figure 1. Force-distance curves. Two typical force-distance curves
when interactions are not detected (black square) and when
interactions are detected (red circle). The unbinding event (or rupture
point) is highlighted by means of the green arrow.
doi:10.1371/journal.pone.0052530.g001
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unbinding events and an overall unbinding probability of about
22%.
Modelling of the GnRH-R rate expression on PC-3 cells
To shed light on the specific dynamic describing the increase in
the exposed receptors, we compared the different amount of
receptors obtained during the treatment time at the two analogue
concentrations used (Fig. 3B). The increase rates were clearly
different but tended to the same value at long times (beyond the
30th day). This behaviour can be paralleled to those observed in
tumor cells where their growth is limited by the finite space in
which cells are confined and by the availability of nutrients, as
modelled by the Gompertz curve [38]:
X (t)~K exp log
X (0)
K
 
exp ({at)
 
where X(t) represents the number of GnRH-R, X(0) the receptor
number at the starting observation time (here normalized to one), K
the maximum number of receptors that can be expressed on the cell
surface and a a constant characterizing the increase rate of GnRH-R.
Figure 3B shows the best-fit curves to the experimental data
obtained for PC-3 cells exposed to 1026 M (red line) or 10211 M
(blue line) LA. In both cases, the remarkable quality of the fit
allows for recovery of receptor increment rate and plateau values.
The plateau value (K = 1.960.1) was the same at both LA
concentrations used. Since K was set to 1 for untreated samples,
the plateau value obtained indicates that in LA-treated PC-3 cells
the receptor number can increase up to 90% compared to
untreated cells, independently of the agonist concentration used.
On the other hand, the increase rate was strongly influenced by
LA concentration [a= (9.360.1) day21 for 1026 M LA and
a= (6.160.1) day21 for 10211 M LA], thus the higher the
concentration the faster the GnRH-R expression.
Topographic distribution of the binding sites
A bidimensional map of unbinding events performed over the
cell surface furnishes a clear visualization of GnRH-R spatial
distribution (Fig. 4). Unbinding events occurring at force ,50 pN
(corresponding to the first peak of the bimodal distribution in
Fig. 2A) are represented in blue, while those in the range of 50–
100 pN (corresponding to the second peak of Fig. 2A), in red. The
spatial distribution of GnRH-R over the PC-3 cell surface appears
Figure 2. LA/GnRH-R unbinding force histograms. Distribution of unbinding events obtained at a loading rate of 2 mm/s in untreated (A) and
LA (1026 M)-treated (B) PC-3 cells after 30 days of culture and in HEK293[SCL60] cells (C). Frequency corresponds to the number of events. In both
untreated and LA-treated PC-3 cells a bimodal distribution (blue line) is clearly detected and quantified by means of two Gaussian distribution curves
(purple and green dashed lines). The first peak was detected at a lower force (f,37 pN) while the second one at a higher force (f,65 pN). In
HEK293[SCL60] cells unbinding events at higher forces are less frequent.
doi:10.1371/journal.pone.0052530.g002
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homogeneous. Treatments with the agonist did not influence the
receptor spatial distribution (Fig. 5) as well as the time intervals but
increased the receptor level. Rarely were some clusters found (data
not shown).
GnRH-R quantification by Western blot analysis
Western blot analysis of GnRH-R-expressing cells
(HEK293[SCL60]) revealed a clear band at approximately
60 kDa, the molecular mass of the type I pituitary receptor
Figure 3. LA/GnRH-R unbinding events. (A) Histograms of LA/GnRH-R unbinding events in LA-treated PC-3 cells. In each measurement,
performed every 6 days, the counting is normalized to that obtained with untreated cells (control) set to 1. Columns, mean; bars, SD. *p,0.001 vs
control, Np,0.001 vs 1026 M LA (one-way ANOVA and Tukey’s multiple comparison tests). (B) Modelling of the GnRH-R rate expression. The amount
of unbinding events detected in PC-3 cells treated with 1026 M LA (blue diamonds) or 10211 M LA (red squares) was normalized to the amount of
unbinding events in untreated cells (control) set to 1. The Gompertz curve was fitted to both the experimental data (blue or red dashed lines). The
GnRH-R increase rates were clearly different [(9.360.1) day21 for 1026 M LA and (6.160.1) day21 for 10211 M LA] but tended to the same value
(1.960.1) at long times (beyond the 30th day). Data are given as mean 6 SD from two independent experiments.
doi:10.1371/journal.pone.0052530.g003
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reported in the literature [39]. PC-3 cells showed a less intense
band at the same position. A negligible signal was detected in non-
transfected HEK293 cells (Fig. 6A).
In PC-3 cells, a 6–30 day treatment with both the LA
concentrations (10211 and 1026 M) induced a statistically
significant increase (from 70% to 110%, p,0.001) in the receptor
levels (Fig. 6B and 6C), supporting data from atomic force
spectroscopy. Even though the highest LA dose seemed to be more
effective in promoting GnRH-R increase, statistical significance
was not always reached (Fig. 6C).
Discussion
The direct extrapituitary effects of GnRH analogues may be
considered the result of a complex mosaic of molecular events that
are necessarily dependent on the amount of GnRH-R molecules
available on the cell surface and the activated signalling pathway,
both of which differ among tissues [4,40].
Figure 4. GnRH-R topography. (A) A representative high-resolution image of the PC-3 cell surface area considered for the receptor mapping. (B) A
representative LA/GnRH-R unbinding force map obtained on PC-3 cells treated for 30 days with 1026 M LA. In blue are represented unbinding events
occurring at force ,50 pN while in red those at force in the range of 50–100 pN.
doi:10.1371/journal.pone.0052530.g004
Figure 5. GnRH-R map of untreated and LA-treated PC-3 cells. The homogeneous distribution of the receptor molecules was not influenced
by the treatment with the analogue (1026 M) and did not vary through the time intervals. In blue are represented unbinding events occurring at
force ,50 pN while in red those at force in the range of 50–100 pN.
doi:10.1371/journal.pone.0052530.g005
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Scarce information is available on the effects of GnRH
analogues on GnRH-R. Most of the published studies on the
effects of GnRH agonists on GnRH-R expression have been
carried out on in vitro and in vivo pituitary models. In these studies,
the observed effects seemed to be strictly dependent on the
administration modality, where a short or pulsatile exposure to the
agonist led to an upregulation of the receptor levels whereas
continuous and prolonged treatments determined a reduction or
left them unchanged [41–43]. In PCa, very heterogeneous results
have been reported. An immunohistochemical study described a
GnRH-R decrease in PCa samples from patients who underwent a
3-month long neoadjuvant hormonal therapy with leuprolide and
the antiandrogen bicalutamide, compared to the immunoreactivity
observed in samples from untreated patients [44]. This finding was
attributed by the authors to the binding of the analogue to PCa
cells. Also in DU-145 xenografted PCas, an agonist-induced slight
decrease in the GnRH-R levels was described, while no significant
variations were observed in the receptor mRNA levels [45].
Similar results were obtained when PCa cells and fibroblasts,
isolated from patients’ samples, were cocultured and exposed to
leuprolide [46]. On the other hand, a strong increase in GnRH-R
mRNA was described in rat prostate after 28 days of treatment
with goserelin [43]. In this context, we observed by Western
blotting that LA was able to induce a post-transcriptional
upregulation of membrane GnRH-R after 4, 6 and 12 days of
treatment in androgen-insensitive, highly invasive and poorly
differentiated PC-3 cells [24].
With the aim of gaining insight into the functional properties of
GnRH-R exposed on cell surface, and therefore actively involved
in the agonist-receptor signalling, an AFM-based approach on
living PC-3 cells was adopted for the first time in the present study.
The effects of a long and continuous treatment with LA on crucial
aspects of the membrane GnRH-R (i.e. quantity of the unbinding
events, strength of the analogue-receptor binding and receptor
distribution) were investigated.
By detecting the amount and the strength of the interaction, we
demonstrated the ability of the hormone to increase the
expression/availability of GnRH-R at the PC-3 cell surface, when
continuously administered to the cells, with a maximum increase
of ,80% after 30 days of treatment with the highest dose of LA.
In this context, we also studied the kinetics of GnRH-R
exposure in PC-3 cells treated with high and low agonist
Figure 6. Western blot analysis of GnRH-R. (A) Western blot analysis of GnRH-R in: PC-3 cells, HEK293 cells (not expressing GnRH-R) and
HEK293[SCL60] cells (stably transfected with GnRH-R) after 6 days of culture. (B) Western blots showing the LA-triggered enhancement of GnRH-R in
PC-3 cells treated for 6–30 days with the analogue (10211 or 1026 M). Representative blots from two separate experiments yielding similar results are
shown. (C) Grouped densitometric data of Western blot analysis of GnRH-R. The intensity of the signals was quantified by densitometric scanning and
normalized to that of b-actin (used as a loading control). Data are the ratio between values of treated and untreated samples (control, set to 1) and
they are shown as mean 6 SD of 2 independent experiments. *p,0.001 vs control, Np,0.001 vs 1026 M LA (one-way ANOVA and Tukey’s multiple
comparison tests).
doi:10.1371/journal.pone.0052530.g006
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concentrations. Kinetics was analyzed by fitting the Gompertz
curve, a logistic curve widely adopted to describe the population
increase in several biologic systems. The Gompertz curve well
recovers the time-dependent increase of the GnRH-R at the cell
surface. According to this model, the rate of expression of GnRH-
R in LA-treated cells depends on the agonist concentration used,
whereas the asymptotic value is independent of the LA concen-
tration and related to the specific cell characteristics and
experimental condition used. This evidence, while clearly estab-
lishing the occurrence of an LA-triggered long-lasting upregulation
of its own receptor at the cell surface, allows for the detection of
the maximum amount of receptors that the cell can express. This
latter finding enables the fine-tuning of the dose/effect ratio by
changing LA concentration. In accordance with the above results
are data from immunoblot analysis of membrane GnRH-R
performed on PC-3 cells treated for 6–30 days with the analogue,
which clearly showed LA efficacy in inducing a significant
upregulation of the receptor, as previously demonstrated by the
same technique until 12 days of treatment [24]. Western blot
findings agree with AFM data as the highest LA dose seemed to be
more efficacious in promoting GnRH-R increase, although
statistical significance was not always reached. This may be due
to the intrinsic differences between the two methods.
As for the mechanisms responsible for the analogue-induced
receptor enhancement, various functional parameters may be
involved in determining the amount of receptors available at the
plasma membrane. Our previous study regarding the LA-induced
upregulation of GnRH-R at the PC-3 cell surface demonstrated
that such effect occurred at a post-transcriptional level [24]. Thus,
it is conceivable that the agonist may act increasing the translation
rate of the receptor transcript and/or slowing protein degradation.
On the basis of literature, it is also possible to speculate that one of
the involved mechanisms may be represented by agonist ability to
promote the GnRH-R exit from the endoplasmic reticulum (ER)
therefore favouring the receptor anterograde trafficking, within
intracellular transport vesicles, to the plasma membrane. This
would be consistent with the observation that other seven
transmembrane (7TM) receptors, such as d-opioid peptide
receptors, that are widely stored within ER, are sent to the cell
surface in response to activation of a small subpopulation of
membrane receptors [47]. Since 7TM receptors also undergo
retrograde transport from the cell surface via endosomes, an
alternative possible explanation is that GnRH-R activation could
inhibit receptor internalization, that for type I mammalian
GnRH-R is known to occur very slowly [48].
The persistence of high receptor levels at the cell surface of
androgen-insensitive cells may warrant the maintenance of their
response to the agonist treatment due to the direct activity of the
hormone. Moreover, accessibility of receptor molecules at the cell
surface may allow for the development of new therapeutic
strategies (i.e. targeted therapies), if confirmed by studies including
other androgen-unresponsive cell lines. However, it remains to be
established whether a similar mechanism also operates in vivo. In
this regard, a clear correlation between the degree of expression of
GnRH-R at the cell surface and the extent of the agonist-induced
antiproliferative response has been demonstrated both in vitro and
in vivo [25]. It has even been hypothesized the usefulness of
patients’ screening and phenotyping in order to select those who
express high levels of GnRH-R at the tumor cell membrane and
thus may benefit from the direct activity of the agonists [49]. The
LA-induced receptor enhancement observed in our study occurred
not only with a high concentration of the analogue but also when a
very low dose (10211 M) was used. In this regard, it is worth
mentioning that in PCa patients who undergo subcutaneous
administration of slow-release preparation of the analogue the
drug plasma concentration reaches values around 1029 M [50].
The unbinding force histograms, recovered by single molecule
force spectroscopy, yield further insights into the biochemical
nature of the GnRH-R. Indeed, the bimodal distribution of the
analogue/GnRH-R interactions in androgen-insensitive PC-3 cells
could be ascribed to several causes: the stochastic presence of non-
specific forces, the simultaneous binding of more than one
receptor, by accidental different orientations of the pulling
direction, or it may suggest the existence of two kinds of receptor.
The latter appears to be the most intriguing since it seems to
indicate the existence of two classes of GnRH-R characterized by
two different binding affinities. Because of the occurrence of a
large number of unbinding events at a lower force, lower affinity
binding sites are prevalent. This finding is in partial agreement
with data from other authors who found a single class of low
affinity binding sites in PC-3 cells [51].
Finally, a homogeneous distribution of the receptor molecules
on the PC-3 cell surface was observed which was not influenced by
the treatment with the analogue and did not vary through the
different time intervals. It has been reported that the GnRH
agonist-receptor complex is initially uniformly distributed on the
surface of the gonadotrope cells [52]. In fact, patching, capping,
microaggregation and internalization of the agonist-receptor
complex begin only a few minutes after the receptor occupancy.
The topographical distribution of the receptors we found on the
PC-3 cell surface is consistent with the fact that only the unbound
fraction of the GnRH-R population has been evaluated by AFM.
In conclusion, our study provides a crucial insight into the
stimulatory effect of LA on GnRH-R expressed on the androgen-
insensitive PCa cell membrane. The information concerning the
ability of the analogue to induce a long-lasting upregulation of its
own receptor at the cell surface may encourage further studies to
verify the possibility of using the analogue in the treatment of
androgen-unresponsive PCa patients by means of its direct activity.
Moreover, this study highlights the fact that AFM, for its
capability to work on living cells and to detect single molecule
interactions, is a powerful tool to investigate important features of
the poorly understood agonist/receptor interaction that could be
used to address structural/chemical analogue optimizations.
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